ProCE Banner Activity

CME

Immune Checkpoint Inhibitor–Based Combinations for Patients With NSCLC and Acquired Resistance to Immunotherapy

Slideset

Download this CME-certified slideset with slidenotes from a virtual roundtable webinar where experts discussed novel approaches to extend the benefits of immunotherapy after disease progression in advanced NSCLC, with a focus on the latest data for combination therapy with immune checkpoint inhibitor therapy plus anti-VEGF(R) therapy.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 06, 2023

Expiration: December 05, 2024

Share

Faculty

Christine M. Bestvina

Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director of Clinical Research
Professor of Medicine
Cedars Sinai
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This program is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the clinical rationale for therapeutic strategies that extend the benefits of immune checkpoint inhibitor therapy after progression

  • Apply available and emerging clinical evidence on IO/anti-VEGF combination therapies to practice for patients with NSCLC who have acquired resistance to ICI therapy

  • Plan therapeutic strategies for patients with advanced or metastatic NSCLC and disease progression on or after ICI-based therapy

  • Manage AEs associated with IO/anti-VEGF combination therapies leveraging the available clinical data and clinical tools

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

Christine M. Bestvina, MD: research support: AstraZeneca, Bristol-Myers Squibb; consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CVS, Daiichi Sankyo, Genentech, Jazz, Johnson & Johnson, Novartis, Pfizer, Regeneron, Sanofi, SeaGen, Takeda, Tempus.

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director of Clinical Research
Professor of Medicine
Cedars Sinai
Los Angeles, California

Karen Reckamp, MD, MS: consultant/advisor/speaker: Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Serono, Genentech, GSK, Janssen, Lilly, Mirati; researcher (paid to institution): Blueprint, Calithera, Daiichi Sankyo, Elevation, Genentech, Janssen. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 06, 2023, through December 05, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.